U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06950086) titled 'Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors' on April 11.
Brief Summary: This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.
Study Start Date: Jan. 02, 2024
Study Type: INTERVENTIONAL
Condition:
HR-positive, HER2-negative Advanced Breast Cancer
Intervention:
DRUG: TYK-00540
Increased dose cohorts from low to MTD (5mg Cohort 1;10 mg Cohort 2; 20 mg Cohort 3; 30 mg Cohort 4;40 mg Cohort 5) decreased dose cohorts for the combination (TYK-00540 30 mg+Fulvestrant Cohort 1;TYK-00540 20mg +...